Vly News - Professional news Platform

In a recent study published in Journal of Physical Chemistry C , researchers demonstrate an approach to detect tyrosinase activity (TYR), an important biomarker for melanoma diagnosis, with the help of an unprecedented surface-enhanced Raman scattering biosensor. Study: Surface Enhanced Raman Scattering Biosensor Based on Self-Assembled Gold Nanorod Array for Fast and Sensitive Tyrosinase Detection . Image Credit: Africa Studio/Shutterstock.com The surface-enhanced Raman scattering biosensor, fabricated on a glass chip, was developed on an array of dopamine-operated Au nanorods (Au NR) that function as capture substrates and 4-mercaptophenylboronic acid (4-MPBA) altered silver nanoparticles (Ag NPs). ) formed a surface-enhanced Raman scattering biosensor probe. Since detecting TYR activity in biological samples is essential for clinical melanoma diagnosis, the proposed approach with various advantages of sensitivity, portability, and reproducibility could be useful for melanoma d

Immunotherapy, such as immune checkpoint inhibitors, has changed the treatment of advanced cancers. Unlike chemotherapy which kills cancer cells, these drugs help the immune system to find and destroy the cancer cells themselves. Unfortunately, only a subset of patients respond to immune checkpoint inhibitors in the long term; and these treatments can be expensive and with side effects. Researchers have developed a two-step approach using whole-exome sequencing to target genes and pathways that predict whether cancer patients will respond to immunotherapy. Studies published in Nature Communication and conducted by researchers at New York University, Weill Cornell Medicine, and the New York Genome Center, illustrates how using whole-exome sequencing can better predict treatment response than current laboratory tests. “Can we better predict who will benefit from immunotherapy? Scientists have developed a variety of biomarkers that help anticipate immunotherapy treatment responses, b